Efficacy and safety of deferiprone for thalassemia: a systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background

Thalassemia is a genetic hemoglobin disorder commonly associated with iron overload and cardiac complications from repeated transfusions. Deferiprone (DFP), an oral iron chelator, has shown potential in reducing body iron and improving cardiac function. This systematic review and meta-analysis evaluates the efficacy and safety of DFP in thalassemia patients.

Methods

A systematic search of PubMed, MEDLINE, and Scopus was conducted from inception to June 8, 2025. Eligible randomized controlled trials (RCTs) enrolled thalassemia patients receiving iron chelation therapy and compared DFP (alone or in combination) with deferoxamine, deferasirox, placebo, or no chelation. Non-randomized studies, those without comparators, or lacking sufficient data were excluded. Risk o

SUBMITTER: Wilar G 

PROVIDER: S-EPMC12821977 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature